ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Nephrology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,598Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 149

$576K Total Retail Price of All Prescriptions

Rank: 5 out of 149

493 Patients Receiving at Least One Drug in Part D
75%Patients 65 Years and Older
51% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Massachusetts
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 493 patients filled at least one prescription for a schedule two drug, compared to an average of 1%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

2% of this provider’s 7,998 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $96 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Massachusetts
FUROSEMIDE 567 496 1 3
LISINOPRIL 557 449 2 1
SIMVASTATIN 478 395 3 5
METOPROLOL TARTRATE 466 343 4 7
OMEPRAZOLE 437 305 5 6
AMLODIPINE BESYLATE 418 309 6 2
HYDROCHLOROTHIAZIDE 342 295 7 11
ATORVASTATIN CALCIUM 197 144 8 15
DOXAZOSIN MESYLATE 193 149 9 24
LOSARTAN POTASSIUM 183 141 10 12
METFORMIN HCL 181 137 11 22
WARFARIN SODIUM 179 165 12 17
SERTRALINE HCL 161 146 13 37
CALCIUM ACETATE 152 97 14 18
PREDNISONE 148 102 15 9
LEVOTHYROXINE SODIUM 147 131 16 19
CITALOPRAM HBR 143 117 17 26
ALLOPURINOL 131 90 18 16
AMITRIPTYLINE HCL 123 75 R 19 88
METOPROLOL SUCCINATE 122 115 20 14
TAMSULOSIN HCL 104 92 21 29
PAROXETINE HCL 102 85 22 58
DONEPEZIL HCL 97 85 23 48
ATENOLOL 96 88 24 20
INSULIN SYRINGE 94 78 25 46
TORSEMIDE 93 80 26 31
ALENDRONATE SODIUM 92 63 27 36
ZOLPIDEM TARTRATE 87 71 28 34
GLIPIZIDE 86 58 29 39
ALPRAZOLAM 85 85 30 103
NIFEDIPINE ER 83 63 31 25
GLIPIZIDE XL 80 68 32 105
POLYETHYLENE GLYCOL 3350 79 39 33 106
ISOSORBIDE MONONITRATE ER 78 71 34 43
KLOR-CON M20 74 61 35 68
PANTOPRAZOLE SODIUM 74 44 35 45
OXYCODONE-ACETAMINOPHEN 70 21 S2 37 41
PROAIR HFA 65 35 38 86
FLUOXETINE HCL 63 18 39 91
HUMULIN N 60 43 40 69
GLYBURIDE 57 55 R 41 47
PRAVASTATIN SODIUM 55 40 42 33
FINASTERIDE 54 54 43 51
DIGOXIN 54 45 43 56
GLIPIZIDE ER 53 41 45 138
SENSIPAR 51 24 46 10
VENLAFAXINE HCL ER 50 32 47 145
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.